HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/lianbio" target="_blank" data-smartkarma-citation="entities:34478:1" rel="noopener">LianBio (LIAN US)</a> is about to officially list on NASDAQ. Based on license-in mode, LianBio has assembled a pipeline of nine assets across five therapeutic areas in less than three years, covering cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. In fact, as of mid-August this year, LianBio ranked first among domestic pharmaceutical companies in terms of the number of license-in projects with five new drugs. The late-stage development pipeline is led by mavacamten, infigratinib, TP-03, NBTXR3 and LYR-210, which would be commercialized in Greater China and other Asian markets. This insight mainly analyzed these late-stage candidates as well as the concerns of the Company.</p>

LianBio (LIAN US) is about to officially list on NASDAQ. Based on license-in mode, LianBio has assembled a pipeline of nine assets across five therapeutic areas in less than three years, covering cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. In fact, as of mid-August this year, LianBio ranked first among domestic pharmaceutical companies in terms of the number of license-in projects with five new drugs. The late-stage development pipeline is led by mavacamten, infigratinib, TP-03, NBTXR3 and LYR-210, which would be commercialized in Greater China and other Asian markets. This insight mainly analyzed these late-stage candidates as well as the concerns of the Company.

Pre-IPO LianBio (LIAN.US) - The Strength and the Concerns

United States

LianBio operates as a biological technology company. The Company develops therapies to treat cardiovascular, oncology, respiratory, ophthalmology and inflammatory disease. LianBio serves customers patients in Asia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pre-IPO LianBio (LIAN.US) - The Strength and the Concerns

The insight mainly analyzed LianBio in terms of late-stage candidates (mavacamten, infigratinib, TP-03, NBTXR3, LYR-210), and concerns on domestic...

Xinyao (Criss) Wang